Retatrutide ReportClinical & Regulatory Intelligence

Comparisons

How Retatrutide Compares

Structured reference comparisons across the leading obesity and metabolic candidates, with the methodological caveats stated up front.

Competitive Landscape

Head-to-head reference cards

Side-by-side reference notes on mechanism, development stage and reported efficacy across leading candidates.

Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.

Retatrutide vs Tirzepatide

Full comparison
Developer
Eli Lilly and CompanyEli Lilly and Company
Mechanism
GLP-1 / GIP / Glucagon triple agonistGLP-1 / GIP dual agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage
Phase 3Approved (obesity, type 2 diabetes)
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes, OSA
Regulatory Status
InvestigationalApproved

Retatrutide vs Semaglutide

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistGLP-1 receptor agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous or oral
Development Stage
Phase 3Approved (obesity, type 2 diabetes)
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes, CV risk
Regulatory Status
InvestigationalApproved

Retatrutide vs CagriSema

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistAmylin analogue + GLP-1 agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage
Phase 3Phase 3 / regulatory submission
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes
Regulatory Status
InvestigationalInvestigational

Retatrutide vs Amycretin

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistAmylin + GLP-1 receptor co-agonist
Administration
Once-weekly subcutaneousSubcutaneous or oral (in development)
Development Stage
Phase 3Phase 2
Studied Population
Obesity ± type 2 diabetesOverweight and obesity
Regulatory Status
InvestigationalInvestigational

Retatrutide vs MariTide

Full comparison
Developer
Eli Lilly and CompanyAmgen
Mechanism
GLP-1 / GIP / Glucagon triple agonistGIP receptor antagonist / GLP-1 agonist
Administration
Once-weekly subcutaneousMonthly or less frequent subcutaneous
Development Stage
Phase 3Phase 3
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes
Regulatory Status
InvestigationalInvestigational

Weekly Briefing

The Retatrutide Report

The most important retatrutide developments, once a week.

  • Clinical trial changes
  • New PubMed research
  • FDA / EMA regulatory developments
  • Eli Lilly announcements
  • Major efficacy and safety updates

No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.